Last Update

2016-08-25T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong David Hallal?

Mr. David L. Hallal

Chief Executive Officer

Alexion Pharmaceuticals Inc

Direct Phone: (203) ***-****       

Email: d***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Alexion Pharmaceuticals Inc

100 College Street

New Haven, Connecticut 06510

United States

Company Description

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion is the global leader in complement inhibition and has developed and commercializes the ... more

Find other employees at this company (3,058)

Background Information

Employment History

National Sales Director

Biogen Idec Inc.

Chief Executive Officer

AGF Management Limited

Affiliations

Board Member
Biotechnology Industry Organization

Board Member
PhRMA companies

Education

BA

University of New Hampshire

Web References (200 Total References)


Leadership: Management & Board Directors | Alexion, Rare Disease Leader

alexion.com [cached]

David Hallal, Chief Executive Officer

...
David Hallal, Alexion - Chief Executive Officer
David Hallal is Chief Executive Officer of Alexion and a member of the company's Board of Directors..
Mr. Hallal was appointed Alexion's second CEO in its 24-year history in April 2015, leading the company to expand its position as the global leader in rare diseases through an important acquisition and the approvals and launches of two highly innovative products. Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading strategic enterprise-wide initiatives that focused on diverse aspects of Alexion's business, including the expansion of the company's research and development pipeline and manufacturing operations. Previously, Mr. Hallal was Alexion's first Chief Commercial Officer.
Mr. Hallal joined Alexion in 2006 to build the company's commercial operations and he led the successful introduction of Soliris ® (eculizumab), the company's first product for two ultra-rare diseases. He played a principal role in leading many significant growth initiatives including the development of Alexion's 50-country operating platform. In addition to his leadership of all global commercial operations, Mr. Hallal has been responsible for country operations in each of Alexion's affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia, and Latin America.
Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexion, he advanced through positions of increasing responsibility in sales, marketing and management at Amgen, Biogen, and OSI Eyetech directing product launches in the areas of hematology, oncology, nephrology and immunology.
Mr. Hallal is a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. He holds a Bachelor of Arts degree from the University of New Hampshire.
...
David Hallal, Chief Executive Officer
David Hallal is Chief Executive Officer of Alexion. Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading strategic enterprise-wide initiatives that focused on diverse aspects of Alexion's operations. He also has served on all key management decision-making committees, and in September 2014 was elected to the Company's Board of Directors. Previously, Mr. Hallal was Alexion's first Chief Commercial Officer.
Mr. Hallal joined Alexion in 2006 to launch the company's commercial operations. He played a principal role in leading many of the company's major growth initiatives and led the highly successful introductions of Soliris® (eculizumab) for both PNH and aHUS, while also building Alexion's 50-country operating platform. In addition to his leadership of all commercial operations globally, Mr. Hallal has been responsible for country operations in each of Alexion's affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia, and Latin America.
Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon, he held commercial leadership positions at OSI Eyetech, Biogen Idec and Amgen where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal holds a BA from the University of New Hampshire.


...

www.sec.gov [cached]

0001457477 Hallal David C/O ALEXION PHARMACEUTICALS, INC 100 COLLEGE STREET NEW HAVEN CT 06510 1 1 0 0 CEO


Dr. Bell is party to a ...

www.sec.gov [cached]

Dr. Bell is party to a consulting agreement with Alexion and Mr. Hallal is party to an employment agreement with Alexion.

...
David Hallal
...
Mr. Hallal became Chief Executive Officer on April 1, 2015. Previously, he was Alexion's Chief Operating Officer since September 2014. From October 2012 to September 2014, Mr. Hallal served as Alexion's Executive Vice President, Chief Commercial Officer. From May 2010 until October 2012, Mr. Hallal was Senior Vice President, Global Commercial Operations and was Senior Vice President, Commercial Operations, Americas from May 2008 until May 2010. Mr. Hallal joined Alexion in June 2006 to build and lead Alexion's U.S. commercial operations, initially with the company's first product launch of Soliris. Prior to joining Alexon in 2006, he had 18 years of commercial operations and leadership experience at a number of companies, including OSI Eyetech, Biogen, Amgen, and Upjohn and he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal holds a BA in Psychology from the University of New Hampshire.
...
In January 2015, Alexion announced the retirement of Dr. Bell, principal founder of Alexion and its only Chief Executive Officer since its inception in 1992, and the election of Mr. Hallal as the Company's second CEO effective April 1, 2015.
...
Mr. Hallal, an Alexion executive since 2006, has been a


...

www.sec.gov [cached]

0001457477 Hallal David C/O ALEXION PHARMACEUTICALS, INC 100 COLLEGE STREET NEW HAVEN CT 06510 1 1 0 0 CEO


"Synageva is an ideal ...

ihif.net [cached]

"Synageva is an ideal strategic and operational fit for Alexion that aligns with what we know well and do well - providing life-transforming therapies to an increasing number of patients with devastating and rare diseases," said Alexion CEO David Hallal.

Similar Profiles

Other People with this Name

Other people with the name Hallal

Rana Hallal
Al-Hadi School

Richie Hallal
Outback Theatre

Joseph Hallal
Phoenix International Pty Ltd

Alexcia Hallal
Premier Strata Management Pty Ltd

Jamil Hallal
Born Interactive

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory